Kathryn F Mileham

12PUBLICATIONS
78CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Apr 30, 2026
Pertuzumab and Trastuzumab in Patients With ERBB2/3-Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry Study.

|Apr 30, 2026
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.

|Oct 16, 2025
Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Tareq Al Baghdadi, Michael Rothe, Pam K Mangat

|Sep 09, 2024
Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non-Small Cell Lung Cancer.

Margaret R Smith, Caroline B Dixon, Yuezhu Wang

|Aug 10, 2023
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.

Herbert L Duvivier, Michael Rothe, Pam K Mangat

|May 26, 2023
Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non-Small Cell Lung Cancer: The Piedmont Study.

Joel R Eisner, Gregory M Mayhew, James M Davison

Pageof 2

Frequent Collaborators

5 joint publications

Elizabeth Garrett-Mayer

5 joint publications

Richard L Schilsky

4 joint publications

Dominique C Hinshaw

4 joint publications

Pam K Mangat